Hostname: page-component-745bb68f8f-hvd4g Total loading time: 0 Render date: 2025-01-12T23:52:43.630Z Has data issue: false hasContentIssue false
  • English
  • Français

Factors Impacting the Selection of Antidepressant Treatment in Patients With Major Depressive Disorder at Risk for Nonadherence

Published online by Cambridge University Press:  07 November 2014

Charles Shelton
Charles Shelton*
Affiliation:
Dr. Shelton is assistant professor of psychiatry at, the University of Kentucky in Lexington, and clinical professor of psychiatry at Pikeville College of Osteopathic Medicine in Kentucky.
*
Charles Shelton, DO, Lexington Psychiatric Group, PSC, 1030 Monarch Street, Suite 100, Lexington, KY 40513; Tel:859-296-0066; Fax: 859-296-1155; E-mail: [email protected].
Get access Rights & Permissions [Opens in a new window]

Abstract

Treatment with the newer generation antidepressants is considered generally effective for most patients with major depressive disorder when taken in accordance with treatment guidelines. However, multiple clinical studies have demonstrated that rates of patient adherence to antidepressants are inadequate, specifically with regard to long-term maintenance treatment. Tolerability issues associated with antidepressants can increase the risk for patient nonadherence and result in subsequent relapse of depressive symptoms. Comorbid symptoms of anxiety also influence psychiatrists' choice of antidepressants for patients with depression. Physicians can improve long-term patient outcomes for patients with major depressive disorder by considering the possibility of drug-drug interactions before prescribing a specific antidepressant.

Type
Research Article
Information
CNS Spectrums , Volume 14 , Issue S12 , 2009 , pp. 15 - 19
Copyright
Copyright © Cambridge University Press 2009

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Practice guideline for the treatment of patients with major depressive disorder (revision). American Psychiatric Association. Am J Psychiatry. 2000;157(4 suppl):1–45.Google Scholar
2.Kobak, KA, Taylor, L, Katzelnick, DJ, Olson, N, Clagnaz, P, Henk, HJ. Antidepressant medication management and Health Plan Employer Data Information Set (HEDIS) criteria: reasons for nonadherence. J Clin Psychiatry. 2002;63(8):727–732.CrossRefGoogle ScholarPubMed
3.Demyttenaere, K, Enzlin, P, Dewé, W, et al.Compliance with antidepressants in a primary care setting, 1: Beyond lack of efficacy and adverse events. J Clin Psychiatry. 2001;62(suppl 22):30–33.Google Scholar
4.Lin, EH, Von Korff, M, Katon, W, et al.The role of the primary care physician in patients' adherence to antidepressant therapy. Med Care. 1995;33(1):67–74.Google Scholar
5.Melartin, TK, Rytsälä, HJ, Leskelä, US, Lestelä-Mielonen, PS, Sokero, TP, Isometsä, ET. Continuity is the main challenge in treating major depressive disorder in psychiatric care. J Clin Psychiatry. 2005;66(2):220–227.Google Scholar
6.Sheehan, DV, Keene, MS, Eaddy, M, Krulewicz, S, Kraus, JE, Carpenter, DJ. Differences in medication adherence and healthcare resource utilization patterns: older versus newer antidepressant agents in patients with depression and/or anxiety disorders. CNS Drugs. 2008;22(11):963–973.Google Scholar
7.Geddes, JR, Carney, SM, Davies, C, et al.Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet. 2003;361(9358):653–661.Google Scholar
8.Melfi, CA, Chawla, AJ, Croghan, TW, Hanna, MP, Kennedy, S, Sredl, K. The effects of adherence to antidepressant treatment guidelines on relapse and recurrence of depression. Arch Gen Psychiatry. 1998;55(12):1128–1132.CrossRefGoogle ScholarPubMed
9.Effexor, XR [package insert]. Philadelphia, PA: Wyeth Pharmaceuticals, Inc.; 2008.Google Scholar
10. Cymbalta [package insert]. Indianapolis, IN: Eli Lilly and Company; 2007.Google Scholar
11. Ixel [package insert]. France: Pierre Fabre Medicaments; 2003.Google Scholar
12.Puozzo, C, Lens, S, Reh, C, et al.Lack of interaction of milnacipran with the cytochrome p450 isoenzymes frequently involved in the metabolism of antidepressants. Clin Pharmacokinet. 2005;44(9):977–988.Google Scholar
13. Savella [package insert]. St. Louis, MO: Forest Pharmaceuticals, Inc.; 2009.Google Scholar
14. Pristiq [package insert]. Philadelphia, PA: Wyeth Pharmaceuticals; 2008.Google Scholar
15.Papakostas, GI. Tolerability of modern antidepressants. J Clin Psychiatry. 2008;69(suppl E1):8–13.Google Scholar
16.Masand, PS. Tolerability and adherence issues in antidepressant therapy. Clin Ther. 2003;25(8):2289–2304.Google Scholar
17.Burra, TA, Chen, E, McIntyre, RS, Grace, SL, Blackmore, ER, Stewart, DE. Predictors of self-reported antidepressant adherence. Behav Med. 2007;32(4):127–134.CrossRefGoogle ScholarPubMed
18.Lin, EH, Von Korff, M, Ludman, EJ, et al.Enhancing adherence to prevent depression relapse in primary care. Gen Hosp Psychiatry. 2003;25(5):303–310.Google Scholar
19.Bull, SA, Hunkeler, EM, Lee, JY, et al.Discontinuing or switching selective serotonin-reuptake inhibitors. Ann Pharmacother. 2002;36(4):578–584.Google Scholar
20.Bull, SA, Hu, XH, Hunkeler, EM, et al.Discontinuation of use and switching of antidepressants: influence of patient-physician communication. JAMA. 2002;288(11):1403–1409.Google Scholar
21.Viale, G. An economic analysis of physician prescribing of selective serotonin reuptake inhibitors. Hosp Pharm. 1998;33(7):847–850.Google Scholar
22.Zimmerman, M, Posternak, M, Friedman, M, et al.Which factors influence psychiatrists' selection of antidepressants? Am J Psychiatry. 2004;161(7):1285–1289.Google Scholar
23.Gorman, JM. Comorbid depression and anxiety spectrum disorders. Depress Anxiety. 1996;4(4):160–168.Google Scholar
24.Ereshefsky, L, Jhee, S, Grothe, D. Antidepressant drug-drug interaction profile update. Drugs R D. 2005;6(6):323–336.Google Scholar
25.Ereshefsky, L, Dugan, D. Review of the pharmacokinetics, pharmacogenetics, and drug interaction potential of antidepressants: focus on venlafaxine. Depress Anxiety. 2000;12(suppl 1):30–44.Google Scholar
26.Ruoff, G. A method that dramatically improves patient adherence to depression treatment. J Fam Pract. 2005;54(10):846–852.Google Scholar
27.Gardner, DM, MacKinnon, N, Langille, D, Andreou, P. Comparison of factors used by physicians and patients in the selection of antidepressant agents. Paper presented at: 17th Congress of the European College of Neuropsychopharmacology; October 9-13, 2004; Stockholm, Sweden.Google Scholar
28.Cates, M. Selecting antidepressant therapy for patients with major depression. Am J Pharm Educ. 2001;65:190–194.Google Scholar